U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H38O7S
Molecular Weight 530.673
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIPELUKAST

SMILES

CCCC1=C(SCCCOC2=CC=C(C(C)=O)C(OCCCC(O)=O)=C2CCC)C=CC(C(C)=O)=C1O

InChI

InChIKey=KPWYNAGOBXLMSE-UHFFFAOYSA-N
InChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)

HIDE SMILES / InChI

Molecular Formula C29H38O7S
Molecular Weight 530.673
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tioxaprofen is a sulfidopeptide leukotriene receptor antagonist. It is an orally bioavailable anti-inflammatory agent, originated by Kyorin Pharmaceutical, which is being developed in clinical trials by the US company MediciNova for the treatment of interstitial cystitis and asthma. The actions of the drug are described by MediciNova as consisting of eosinophil migration inhibition, leukotriene antagonism, and phosphodiesterase IV inhibition. Other mechanisms described for Tioxaprofen include the inhibition of phosphodiesterases III, 5-lipoxygenase, phospholipase C as well as thromboxane A2. Tioxaprofen in doses of 1 and 5 mg/kg inhibits bronchoconstriction induced by inhalation of antigen and propranolol in a dose-dependent manner. Tioxaprofen was in phase III clinical trial for the treatment of asthma. However, this development was discontinued. It is under investigation for the treatment of idiopathic pulmonary fibrosis and Non-alcoholic steatohepatitis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P09917
Gene ID: 240.0
Gene Symbol: ALOX5
Target Organism: Homo sapiens (Human)
1.11 µM [IC50]
0.567 µM [IC50]
0.639 µM [IC50]
PubMed

PubMed

TitleDatePubMed
MN 001: KCA 757, KCA-757, MN-001.
2007
Gateways to clinical trials.
2007 Jun
Patents

Sample Use Guides

750 mg twice daily, 500 mg three times daily
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:49:44 UTC 2023
Edited
by admin
on Fri Dec 15 15:49:44 UTC 2023
Record UNII
08379P260O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIPELUKAST
INN   MART.   USAN  
INN   USAN  
Official Name English
TIPELUKAST [MART.]
Common Name English
TIPELUKAST [USAN]
Common Name English
KCA-757
Code English
MN-001
Code English
Tipelukast [WHO-DD]
Common Name English
tipelukast [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29712
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
FDA ORPHAN DRUG 448914
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
Code System Code Type Description
FDA UNII
08379P260O
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
ChEMBL
CHEMBL2104988
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
DRUG BANK
DB12435
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
INN
8741
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
SMS_ID
300000034380
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
PUBCHEM
9893228
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
USAN
RR-119
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
NCI_THESAURUS
C74581
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
EPA CompTox
DTXSID00925325
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
CAS
125961-82-2
Created by admin on Fri Dec 15 15:49:44 UTC 2023 , Edited by admin on Fri Dec 15 15:49:44 UTC 2023
PRIMARY
Related Record Type Details
TARGET->INHIBITOR OF EXPRESSION
TARGET->INHIBITOR OF EXPRESSION
TARGET->INHIBITOR OF EXPRESSION
TARGET -> INHIBITOR
TARGET->INHIBITOR OF EXPRESSION
Related Record Type Details
ACTIVE MOIETY